<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1887-8571</journal-id>
<journal-title><![CDATA[Sanidad Militar]]></journal-title>
<abbrev-journal-title><![CDATA[Sanid. Mil.]]></abbrev-journal-title>
<issn>1887-8571</issn>
<publisher>
<publisher-name><![CDATA[Ministerio de Defensa]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1887-85712024000300007</article-id>
<article-id pub-id-type="doi">10.4321/s1887-85712024000300007</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Evaluación positiva de medicamentos: marzo, abril y mayo de 2024]]></article-title>
<article-title xml:lang="en"><![CDATA[Positive assessment of drugs: March, April and May of 2024]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Silva-Cuevas]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Porras-Zarta]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-Sánchez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Villacorta Sanz]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Central de la Defensa Gómez Ulla Servicio de Farmacología Clínica ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Central de la Defensa Gómez Ulla Servicio de Farmacia Hospitalaria ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Central de la Defensa Gómez Ulla Servicio de Farmacia Hospitalaria ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2024</year>
</pub-date>
<volume>80</volume>
<numero>3</numero>
<fpage>145</fpage>
<lpage>150</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1887-85712024000300007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1887-85712024000300007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1887-85712024000300007&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN Se reseñan los medicamentos evaluados y con dictamen positivo por comisión de expertos de la Agencia Española de Medicamentos y Productos Sanitarios o de la Agencia Europea del Medicamento hechos públicos en marzo, abril y mayo de 2024, y considerados de mayor interés para el profesional sanitario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[SUMMARY The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in March, April and May of 2024, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[aprocitentán (Jeraygo®)]]></kwd>
<kwd lng="es"><![CDATA[aztreonam/avibactam (Emblaveo®)]]></kwd>
<kwd lng="es"><![CDATA[bevacizumab gamma (Lytenava®)]]></kwd>
<kwd lng="es"><![CDATA[capivasertib (Truqap®)]]></kwd>
<kwd lng="es"><![CDATA[cloruro de galio (68ga) (Galliapharm®)]]></kwd>
<kwd lng="es"><![CDATA[dasiglucagon (Zegalogue®)]]></kwd>
<kwd lng="es"><![CDATA[efanesoctocog alfa (Altuvoct®)]]></kwd>
<kwd lng="es"><![CDATA[fidanacogen elaparvovec (Durveqtix®)]]></kwd>
<kwd lng="es"><![CDATA[fruquintinib (Fruzaqla®)]]></kwd>
<kwd lng="es"><![CDATA[iptacopan (Fabhalta®)]]></kwd>
<kwd lng="es"><![CDATA[insulina icodec (Awiqli®)]]></kwd>
<kwd lng="es"><![CDATA[polihexanida (Akantior®)]]></kwd>
<kwd lng="es"><![CDATA[forma recombinante de la adamts13 endógena (Adzynma®)]]></kwd>
<kwd lng="es"><![CDATA[sugemalimab (Cejemly®)]]></kwd>
<kwd lng="es"><![CDATA[vacuna chicungunya (Ixchiq®)]]></kwd>
<kwd lng="es"><![CDATA[vacuna de la influenza virus vaccine (Fluenz®)]]></kwd>
<kwd lng="es"><![CDATA[vibegrón (Obgemsa®)]]></kwd>
<kwd lng="en"><![CDATA[aprocitentán (Jeraygo®)]]></kwd>
<kwd lng="en"><![CDATA[aztreonam/avibactam (Emblaveo®)]]></kwd>
<kwd lng="en"><![CDATA[bevacizumab gamma (Lytenava®)]]></kwd>
<kwd lng="en"><![CDATA[capivasertib (Truqap®)]]></kwd>
<kwd lng="en"><![CDATA[cloruro de galio (68ga) (Galliapharm®)]]></kwd>
<kwd lng="en"><![CDATA[dasiglucagon (Zegalogue®)]]></kwd>
<kwd lng="en"><![CDATA[efanesoctocog alfa (Altuvoct®)]]></kwd>
<kwd lng="en"><![CDATA[fidanacogen elaparvovec (Durveqtix®)]]></kwd>
<kwd lng="en"><![CDATA[fruquintinib (Fruzaqla®)]]></kwd>
<kwd lng="en"><![CDATA[iptacopan (Fabhalta®)]]></kwd>
<kwd lng="en"><![CDATA[insulina icodec (Awiqli®)]]></kwd>
<kwd lng="en"><![CDATA[polihexanida (Akantior®)]]></kwd>
<kwd lng="en"><![CDATA[forma recombinante de la adamts13 endógena (Adzynma®)]]></kwd>
<kwd lng="en"><![CDATA[sugemalimab (Cejemly®)]]></kwd>
<kwd lng="en"><![CDATA[vacuna chicungunya (Ixchiq®)]]></kwd>
<kwd lng="en"><![CDATA[vacuna de la influenza virus vaccine (Fluenz®)]]></kwd>
<kwd lng="en"><![CDATA[vibegrón (Obgemsa®)]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<collab>AEMPS</collab>
<source><![CDATA[Reunión del Comité de Medicamentos de uso Humano (CHMP) de abril 2024]]></source>
<year>2024</year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<collab>European Medicines Agency</collab>
<source><![CDATA[Ficha técnica de Jeraygo(r)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schlaich]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Bellet]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Weber]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Danaietash]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Bakris]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
<name>
<surname><![CDATA[Flack]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2022</year>
<volume>400</volume>
<page-range>1927-37</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="">
<collab>AEMPS</collab>
<source><![CDATA[Reunión del Comité de Medicamentos de uso Humano (CHMP) de marzo 2024]]></source>
<year>2024</year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="">
<collab>European Medicines Agency</collab>
<source><![CDATA[Ficha técnica de Emblaveo(r)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="">
<collab>European Medicines Agency</collab>
<source><![CDATA[EPAR-Product Information of Emblaveo(r)]]></source>
<year>2024</year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<collab>European Medicines Agency</collab>
<source><![CDATA[Ficha técnica de Lytenava(r)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="">
<collab>European Medicines Agency</collab>
<source><![CDATA[EPAR-Product Information of Lytenava(r)]]></source>
<year>2024</year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="">
<collab>European Medicines Agency</collab>
<source><![CDATA[Ficha técnica de Truqap(r)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Turner]]></surname>
<given-names><![CDATA[NC]]></given-names>
</name>
<name>
<surname><![CDATA[Oliveira]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Howell]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Dalenc]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Cortes]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gomez Moreno]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Capivasertib in hormone receptor-positive advanced breast cancer]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2023</year>
<volume>388</volume>
<page-range>2058-70</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="">
<collab>AEMPS</collab>
<source><![CDATA[Reunión del Comité de Medicamentos de uso Humano (CHMP) de mayo 2024]]></source>
<year>2024</year>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="">
<collab>EMA</collab>
<source><![CDATA[Reunión del Comité de Medicamentos de uso Humano (CHMP). Summary of opinion Galliapharm(r)]]></source>
<year>2024</year>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="">
<collab>AEMPS. Centro de información online de medicamentos de la AEMPS - CIMA</collab>
<source><![CDATA[Ficha técnica Galliapharm(r)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="">
<collab>EMA</collab>
<source><![CDATA[Reunión del Comité de Medicamentos de uso Humano (CHMP). Summary of opinion Zegalogue(r)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="book">
<collab>U.S. Food and Drug Administration</collab>
<source><![CDATA[Highlights of prescribing information: Zegalogue(r)]]></source>
<year></year>
<publisher-loc><![CDATA[Silver Spring (MD) ]]></publisher-loc>
<publisher-name><![CDATA[U.S. Food and Drug Administration]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="">
<collab>European Medicines Agency</collab>
<source><![CDATA[Ficha técnica de Altuvoct(r)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Drygalski]]></surname>
<given-names><![CDATA[A von]]></given-names>
</name>
<name>
<surname><![CDATA[Chowdary]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Kulkarni]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Susen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Konkle]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Oldenburg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efanesoctocog Alfa prophylaxis for patients with severe hemophilia A]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2023</year>
<volume>388</volume>
<page-range>310-8</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="">
<collab>EMA</collab>
<source><![CDATA[Reunión del Comité de Medicamentos de uso Humano (CHMP). Summary of opinion Durveqtix(r)]]></source>
<year>2024</year>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pittman]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Carrieri]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Soares]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[McKay]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Liang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Field Study and Correlative Studies of Factor IX Variant FIX-R338L in Participants Treated with Fidanacogene Elaparvovec]]></article-title>
<source><![CDATA[Thromb Haemost]]></source>
<year>2024</year>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="">
<collab>European Medicines Agency</collab>
<source><![CDATA[Ficha técnica de Fruzaqla(r)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dasari]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lonardi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia-Carbonero]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Elez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshino]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Sobrero]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2023</year>
<volume>402</volume>
<page-range>41-53</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="">
<collab>European Medicines Agency</collab>
<source><![CDATA[Ficha técnica de Fabhalta(r)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peffault de Latour]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Röth]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kulasekararaj]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Scheinberg]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Maciejewski]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2024</year>
<volume>390</volume>
<page-range>994-1008</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="">
<collab>European Medicines Agency</collab>
<source><![CDATA[Ficha técnica de Awiqli(r)]]></source>
<year>2024</year>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shetty]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Suvarna]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of once-weekly insulin icodec in type 2 diabetes: A meta-analysis of ONWARDS phase 3 randomized controlled trials]]></article-title>
<source><![CDATA[Diabetes Obes Metab]]></source>
<year>2024</year>
<volume>26</volume>
<page-range>1069-81</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="">
<collab>EMA</collab>
<source><![CDATA[Reunión del Comité de Medicamentos de uso Humano (CHMP). Summary of opinion Durveqtix(r)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dart]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Papa]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Rama]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Knutsson]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ahmad]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hau]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sanchez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Orphan Drug for Acanthamoeba Keratitis (ODAK) Trial: PHMB 0.08 % (Polihexanide) and Placebo versus PHMB 0.02 % and Propamidine 0.1]]></article-title>
<source><![CDATA[Ophthalmology]]></source>
<year>2024</year>
<volume>131</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>277-87</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="">
<collab>EMA</collab>
<source><![CDATA[Reunión del Comité de Medicamentos de uso Humano (CHMP). Summary of opinion Adzynma(r)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="book">
<collab>U.S. Food and Drug Administration</collab>
<source><![CDATA[Highlights of prescribing information: Adzynma(r)]]></source>
<year>2023</year>
<publisher-loc><![CDATA[Silver Spring (MD) ]]></publisher-loc>
<publisher-name><![CDATA[U.S. Food and Drug Administration]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="">
<collab>EMA</collab>
<source><![CDATA[Reunión del Comité de Medicamentos de uso Humano (CHMP). Summary of opinion Cejemly(r)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dhillon]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Duggan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sugemalimab First Approval]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>2022</year>
<volume>82</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>593-9</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="">
<collab>European Medicines Agency</collab>
<source><![CDATA[EPAR-Product Information of Ixchiq(r)]]></source>
<year>2024</year>
</nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="">
<collab>European Medicines Agency</collab>
<source><![CDATA[EPAR-Risk managment plan of Ixchiq(r)]]></source>
<year>2024</year>
</nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="">
<collab>European Medicines Agency</collab>
<source><![CDATA[EPAR-Product Information of Fluenz(r)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="">
<collab>European Medicines Agency</collab>
<source><![CDATA[EPAR-Risk managment plan of Fluenz(r)]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="">
<collab>European Medicines Agency</collab>
<source><![CDATA[Ficha técnica de Obgemsa(r)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Staskin]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Frankel]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Varano]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Shortino]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Jankowich]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mudd Jr]]></surname>
<given-names><![CDATA[PN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[International phase III, randomized, double-blind, placebo and active controlled study to evaluate the safety and efficacy of vibegron in patients with symptoms of overactive bladder: EMPOWUR]]></article-title>
<source><![CDATA[J Urol]]></source>
<year>2020</year>
<volume>204</volume>
<page-range>316-24</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
